A Deeper Dive Into Advanced and Future Directions in Treating Patients With Acute Myeloid Leukemia

Pamela

doi:10.6004/jadpro.2018.9.3.11

Abstract

Acute myeloid leukemia is a disease that affects predominantly older patients, with a median age at diagnosis of 68. Overall prognosis is poor, but novel therapies that have emerged in recent years offer hope that outcomes can improve. In this comprehensive presentation, speakers covered a broad array of topics, including diagnostic workup, risk stratification, and novel therapeutic agents, and walked listeners through three illustrative case presentations.

Highlights

RISK FACTORS, SIGNS, AND SYMPTOMS A major contributing factor to the poor prognosis of acute myelogenous leukemia (AML) is the lack of established risk factors that would afford opportunities for prevention
Certain environmental or occupational exposures have been implicated in the etiology of AML, along with iatrogenic and genetic factors that apply to a relatively small proportion of patients (Table 1)
In the 2016 World Health Organization (WHO) classification of myeloid neoplasms, AML is characterized as a complex, dynamic disease with multiple somatically acquired driver mutations, coexisting competing clones, and disease evolution over time (Arber et al, 2016)

Summary

MEETING REPORTS

A Deeper Dive Into Advanced and Future Directions in Treating Patients With Acute Myeloid Leukemia. Multiple new and novel therapies have emerged in recent years, offering encouragement that outcomes in AML, including survival, will improve. RISK FACTORS, SIGNS, AND SYMPTOMS A major contributing factor to the poor prognosis of AML is the lack of established risk factors that would afford opportunities for prevention. In more than 80% of new diagnoses, patients have no recognized risk factors, said Ms Kurtin. There are two groups of patients with tAML; those whose disease occurs 5 to 10 years after treatment of the primary malignancy with regimens that include alkylating agents such as cyclophosphamide and other agents such as cisplatin and carboplatin, and those whose disease occurs 2 to 3 years after treatment of the primary malignancy with topoisomerase II inhibitors such as etoposide or the anthracyclines. In subtypes of AML, patients may develop skin nodules or

ACUTE MYELOID LEUKEMIA

KURTIN and ZECHA

Findings

RR AML